The European Medicines Agency (EMA) has published new product information wording extracts from the Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals adopted at its 7-10 April 2026 meeting. The document, released on 4 May 2026, provides updated safety information for several medicines, impacting healthcare professionals, patients, and marketing authorisation holders across the EU.
The document is a formal output of the PRAC, EMA's committee responsible for assessing and monitoring the safety of human medicines. It contains the exact wording to be included in the summary of product characteristics (SmPC) and package leaflet for each affected product. These updates are mandatory for marketing authorisation holders, who must implement the changes within a specified timeframe set by the PRAC.
Policy orientations and trade-offs The PRAC's recommendations aim to enhance patient safety by updating product information based on new safety data. This involves a trade-off between ensuring timely communication of risks and the administrative burden on pharmaceutical companies to update labelling. The updates may also lead to more restrictive use of certain medicines, potentially limiting treatment options for some patients while reducing adverse events.
Impact on stakeholders - Patients: Benefit from clearer safety information, enabling informed decisions, but may face restricted access if indications are narrowed. - Healthcare professionals: Receive updated guidance on prescribing and monitoring, improving clinical decision-making but requiring adaptation to new protocols. - Marketing authorisation holders: Must implement labelling changes, incurring costs and regulatory compliance efforts. - EU regulatory bodies: Ensure consistent safety communication across member states, reinforcing pharmacovigilance standards.
Expected institutional follow-up Marketing authorisation holders are expected to submit variations to their marketing authorisations to reflect the new wording. National competent authorities will oversee implementation. The next PRAC meeting will review compliance and may issue further recommendations if additional safety signals emerge.
← Atlas › News › Health & Lifestyle